Innovative Eyewear (LUCYW) Files Form 144 for 3,009 Share Sale via Raymond James
Rhea-AI Filing Summary
Innovative Eyewear, Inc. (LUCYW) Form 144 reports a proposed sale of 3,009 common shares to be executed through Raymond James & Associates on 08/19/2025 on NASDAQ. The filing lists an aggregate market value of $5,894.17 for the shares and states total shares outstanding of 4,574,602, providing the basic size and timing of the planned transaction.
The securities were acquired as an RSU grant on 08/19/2025 (noted amount: 9,600 shares) with cash listed as the payment type. The filer attests by signature that they do not possess undisclosed material adverse information about the issuer.
Positive
- Clear disclosure of broker, number of shares, aggregate market value, and exchange (NASDAQ)
- Acquisition details provided (RSU grant and date) which support transparency around the provenance of the shares
- Filer attestation that they do not possess undisclosed material adverse information
Negative
- None.
Insights
TL;DR: Routine Form 144 filing disclosing an intended sale of restricted stock via a broker with required attestation.
The filing presents the standard disclosures required under Rule 144: identity of broker, number of shares proposed for sale, market value, and outstanding shares. It also documents the acquisition as an RSU grant and includes the attestation that no material nonpublic information is known to the seller. From a compliance perspective, the form contains the necessary elements to support an issuer-affiliated sale under Rule 144 procedures.
TL;DR: Small, routine insider sale disclosed; limited investor impact based on disclosed size and value.
The transaction size—3,009 shares worth $5,894.17—represents a very small portion of the stated outstanding share count (4,574,602). The acquisition origin is an RSU grant dated the same day, and the sale will route through a listed broker on NASDAQ. Based solely on the filing's figures, this appears operationally routine and not material to equity valuation.